Long-term impact of growth hormone therapy on mortality and type 2 diabetes in Prader–Willi syndrome: a nationwide cohort study
BackgroundPrader–Willi syndrome (PWS) is a rare genetic disorder characterized by severe multisystem comorbidities and increased mortality. Although growth hormone therapy (GHT) is widely used as standard care, population-based evidence on its long-term safety, particularly in relation to mortality...
Saved in:
| Main Authors: | Yong Jun Choi, Aram Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1642129/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prader-Willi Syndrome in Neonates
by: J Gordon Millichap
Published: (1990-12-01) -
Physical activity in the management of obesity in prader-willi syndrome
by: Bartosz Łuniewski, et al.
Published: (2025-05-01) -
Prader-Willi syndrome with nephrotic syndrome:one case report
by: Zhang Li, et al.
Published: (2022-02-01) -
Management of Hyperphagia and Obesity in Prader–Willi
Syndrome
by: JiHoon Hwang, et al.
Published: (2023-12-01) -
Updates on Obesity in Prader-Willi Syndrome: From Genetics to
Management
by: Young Bae Sohn, et al.
Published: (2023-12-01)